HALO

Halozyme Therapeutics, Inc. Press Releases

$9.62
*  
0.28
3%
Get HALO Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading HALO now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    HALO After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer
12/19/2014 8:30:00 AM - PR Newswire
▲4.34 % Price Change since this news event. The Volume Ratio is 3.27.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Deal Street: Analyst Coverage on Visteon, Halozyme, Coca-Cola, Groupon and Barrick Gold
12/18/2014 9:30:00 AM - PR Newswire


Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE™ Technology
12/17/2014 9:00:00 AM - PR Newswire
▲25.92 % Price Change since this news event. The Volume Ratio is 2.08.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting
12/12/2014 8:00:00 AM - PR Newswire
▲19.65 % Price Change since this news event. The Volume Ratio is 1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference
12/3/2014 4:15:00 PM - PR Newswire
▲11.21 % Price Change since this news event. The Volume Ratio is 1.04.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
11/25/2014 4:15:00 PM - PR Newswire


Halozyme Reports Third Quarter 2014 Financial Results
11/10/2014 4:05:00 PM - PR Newswire
▲3.55 % Price Change since this news event. The Volume Ratio is 3.33.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
11/5/2014 4:15:00 PM - PR Newswire
▲6.53 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Halozyme to Host Third Quarter 2014 Financial Results Conference Call
11/3/2014 4:15:00 PM - PR Newswire
▲1.26 % Price Change since this news event. The Volume Ratio is 0.69.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency
10/20/2014 9:00:00 AM - Business Wire


Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant
10/20/2014 8:30:00 AM - PR Newswire


Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant
10/20/2014 8:30:00 AM - PR Newswire
▲7.73 % Price Change since this news event. The Volume Ratio is 0.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Halozyme Announces Podium Presentation On PEGPH20 At The New York Academy Of Sciences
10/9/2014 9:00:00 AM - PR Newswire
▲5.71 % Price Change since this news event. The Volume Ratio is 1.2.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Halozyme Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20
10/7/2014 8:30:00 AM - PR Newswire


Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer
10/3/2014 7:45:00 AM - PR Newswire